What is the appropriate treatment for hidradenitis suppurativa at each Hurley stage (I, II, III)?

Treatment of Hidradenitis Suppurativa by Hurley Stage

For Hurley Stage I disease, start with topical clindamycin 1% solution; for Hurley Stage II, use combination clindamycin 300 mg + rifampin 300 mg twice daily for 8-12 weeks or adalimumab; for Hurley Stage III, initiate adalimumab as first-line with surgical excision for definitive management. 1, 2

Hurley Stage I Treatment Algorithm

First-line therapy:

• Topical clindamycin 1% solution is the only topical antibiotic with RCT evidence, demonstrating reduced pustules in a 12-week trial, though it has no effect on inflammatory nodules and abscesses 1
• Consider adding benzoyl peroxide to reduce Staphylococcus aureus resistance risk 1
• Intralesional triamcinolone (10 mg/mL, 0.2-2.0 mL) provides rapid pain relief within 1 day and reduces erythema, edema, and suppuration 1

Second-line options:

• Oral tetracycline 500 mg twice daily achieves 30% reduction in abscesses 1
• Doxycycline 100 mg twice daily (though evidence is limited) 1

Procedural interventions:

• Nd:YAG laser is recommended based on RCT data for Stage II/III and expert consensus for Stage I 3
• Deroofing or excision for recurrent nodules and tunnels 3
• Incision and drainage ONLY for acute abscesses to relieve pain—not for definitive treatment 3

Hurley Stage II Treatment Algorithm

First-line therapy:

• Clindamycin 300 mg + rifampin 300 mg, both twice daily for 8-12 weeks shows 71-93% response rates across 187 patients 1
• Adalimumab is rated most effective by patients and has strong recommendation in the 2026 guidelines 4, 2

Second-line options:

• Triple therapy: moxifloxacin 400 mg daily + metronidazole 500 mg three times daily + rifampin 300 mg twice daily
  • 8 of 10 Stage II patients achieved complete response 1
  • Stop metronidazole at 6 weeks to avoid neurologic toxicity 1
  • Use as bridge to surgery or long-term therapy 1

Third-line rescue therapy:

• Intravenous ertapenem 1 g daily for 6 weeks achieves clinical remission in most Stage I/II areas, but relapses are frequent 1
• Reserved for surgical planning or rescue due to practical barriers and antibiotic resistance concerns 1

Procedural interventions:

• Nd:YAG laser has RCT evidence for Stage II disease 3
• CO2 laser excision for fibrotic sinus tracts 3
• Wide local excision with various closure methods for extensive chronic lesions 3

Hurley Stage III Treatment Algorithm

First-line therapy:

• Adalimumab receives strong recommendation and is rated most effective by patients 2, 4
• Bimekizumab, infliximab, and secukinumab also have strong recommendations 2

Adjunctive systemic antibiotics:

• Clindamycin + rifampin as adjuvant therapy (lower response rates in advanced disease but useful perioperatively) 1
• Triple therapy (moxifloxacin + metronidazole + rifampin): only 2 of 12 Stage III patients achieved complete response 1
• Dapsone shows NO response in Stage III disease 1

Surgical management:

• Wide local excision is favored over less extensive techniques with lower recurrence rates (overall 16.2%) and complication rates (11.1%) 5
• Continue medical therapy perioperatively—poses minimal risk and likely beneficial 3
• Wound healing options: secondary intention, primary closure, delayed primary closure, flaps, grafts, or skin substitutes 3

Procedural adjuncts:

• Nd:YAG laser has RCT evidence for Stage III 3
• CO2 laser excision for fibrotic sinus tracts 3

Critical Caveats

Common pitfalls to avoid:

• Do NOT use incision and drainage as definitive treatment—it only provides temporary pain relief and does not address underlying disease 3
• Do NOT expect dapsone to work in Stage III disease 1
• Do NOT continue metronidazole beyond 6 weeks due to neurologic toxicity risk 1
• Do NOT use monotherapy antibiotics alone in advanced disease—they have lower response rates and increased recurrence 1

Pain management:

• Routine pain assessment receives strong recommendation 2
• Higher Hurley stages require more aggressive pain management including NSAIDs and potentially opioids 6

Supportive measures across all stages:

• Tobacco cessation (conditional recommendation) 2
• Zinc supplementation and vitamin D repletion (conditional recommendation) 2
• Antiseptic washes (generally supported, low risk of contact dermatitis) 3

The 2026 AAD-HSF guidelines provide the most current evidence-based framework, making strong recommendations for biologics (adalimumab, bimekizumab, infliximab, secukinumab) and conditional recommendations for various antibiotics and procedural interventions 2. The key principle is escalating therapy intensity with disease severity while recognizing that Stage III disease requires biologics and surgery for optimal outcomes.